Research & Development
-
Alamy
Beyond Botox: AbbVie’s push for broader gains in neurotoxin R&D
The large pharma is advancing two next-generation neurotoxins in both the therapeutic and aesthetic spaces.
By Alexandra Pecci • Dec. 23, 2025 -
Getty Images
Biopharma CEO optimism is wavering in the US
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
By Kelly Bilodeau • Dec. 22, 2025 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Permission granted by Biogen
Q&ABiogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth
Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.
By Michael Gibney • Dec. 19, 2025 -
Getty Images
The leading GLP-1 contenders in pharma’s race for an obesity pill
Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape.
By Alivia Kaylor • Dec. 18, 2025 -
Getty Images
3 key takeaways from the FDA’s new animal testing guidance
The agency’s moves to end animal testing are “not a fluke.” Here’s what drugmakers need to know about where it goes from here.
By Alexandra Pecci • Dec. 17, 2025 -
Retrieved from FDA.
How the FDA could soon upend vaccine trials
Vaccinemakers should be prepared to pivot to meet new requirements by ensuring strong communication.
By Kelly Bilodeau • Dec. 17, 2025 -
Permission granted by Amylyx Pharmaceuticals
Amylyx pins its next hopes on a niche drug in the obesity space
A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.
By Meagan Parrish • Dec. 12, 2025 -
Courtesy of Johnson & Johnson
Pharma’s top deals in 2025
The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.
By Michael Gibney • Dec. 11, 2025 -
Getty Images
Another genetic testing company? Why a different approach could boost drug predictions and R&D.
Genetic tests could soon play a larger role in clinical trials and predicting adverse events.
By Alexandra Pecci • Dec. 10, 2025 -
Permission granted by Eli Lilly
Q&AHow Lilly uses Big Pharma heft to lift up-and-coming biotechs
With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.
By Michael Gibney • Dec. 9, 2025 -
Permission granted by BeOne
Q&ABeOne brought Brukinsa to the blood cancer mountaintop. Can it hit those heights again?
The company’s chief medical officer discusses its trajectory with the blockbuster Brukinsa and its strong hematology pipeline.
By Michael Gibney • Dec. 4, 2025 -
Sarah Silbiger via Getty Images
4 major changes at the FDA this year
The most impactful regulatory shifts for pharma in 2025 and how the industry can take advantage of new policies.
By Alexandra Pecci • Dec. 3, 2025 -
Getty Images
Hemophilia gene therapies are struggling on the market, even as innovation soars
The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.
By Kelly Bilodeau • Dec. 3, 2025 -
Getty Images
Novo, J&J Alzheimer’s clinical flops teach bruised field valuable lessons
November was a tough month for highly anticipated Alzheimer’s readouts with a GLP-1 and tau-targeting drug coming up short in late-stage trials.
By Michael Gibney • Dec. 2, 2025 -
Getty Images
A drugmaker charts a path through pharma’s ethical minefields
As the science behind pharma breakthroughs becomes more complex, bioethicists are helping companies navigate moral quandaries.
By Kelly Bilodeau • Dec. 1, 2025 -
Getty Images
Along with NIH cuts come risks to patient safety and scientific data
The abrupt withdrawal of research funds affected 74,000 clinical trial participants, including some already taking the drugs being studied.
By Kelly Bilodeau • Nov. 26, 2025 -
Getty Images
What’s next in the eye disease pipeline?
An early gene therapy breakthrough spurred investments, but can the industry maintain momentum?
By Kelly Bilodeau • Nov. 24, 2025 -
Courtesy of Madrigal
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.
By Kelly Bilodeau • Nov. 19, 2025 -
Getty Images
Amylin could reign supreme in the next wave of obesity drugs
With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.
By Alivia Kaylor • Nov. 18, 2025 -
Permission granted by Pfizer
Sponsored by PfizerDeveloping a path forward in cancer cachexia
Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.
Nov. 17, 2025 -
Getty Images
The next leap in Alzheimer’s R&D is coming, but not around the corner
While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.
By Alexandra Pecci • Nov. 17, 2025 -
Permission granted by Alnylam
ProfileRNAi looked doomed to fail — until Alnylam’s science chief found a way
Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.
By Michael Gibney • Nov. 13, 2025 -
Permission granted by Sarepta Therapeutics
Drugs are winning approval even when trials fail — but should they?
About 10% of FDA-approved drugs in recent years have won clearance despite a trial failure, raising safety and ethical concerns.
By Kelly Bilodeau • Nov. 12, 2025 -
Permission granted by eClinical Solutions
Pharma’s clinical trial diversity push faces a new threat
Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.
By Meagan Parrish • Nov. 7, 2025 -
Getty Images
Why Pfizer and Novo are duking it out over weight loss startup Metsera
A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.
By Michael Gibney • Nov. 6, 2025
